N@N

Li Watsek Reiterated (ASND) at Buy and Held Target at $152 on, Sep 15th, 2023

Li Watsek of Cantor Fitzgerald, Reiterated "Ascendis Pharma A/S" (ASND) at Buy and Held Target at $152 on, Sep 15th, 2023.

Li has made no other calls on ASND in the last 4 months.

There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 2 agree with Li's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $113 on, Wednesday, September 6th, 2023
• Tiago Fauth of "Credit Suisse" Initiated at Hold and Held Target at $89 on, Wednesday, June 14th, 2023

These are the ratings of the 2 analyists that currently disagree with Li

---

• Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $192 on, Wednesday, September 6th, 2023
• Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $134 on, Wednesday, September 6th, 2023

Contributing Sources

---